Articles, insights, and posts about Child Development, early detection, and new methods in diagnosis and treatment.
At FDNA, we’re making precision medicine a reality by crowdsourcing knowledge and integrating next-generation phenotyping (NGP) technologies into every patient evaluation. NGP is the computational capture, analysis and integration of phenotypic data into health analysis—a hallmark of FDNA’s technologies. In 2017, our Face2Gene application turned five, and alongside our collaborators, we marked some serious milestones: […]
In an era of breakthrough advancements in healthcare, it is hard to believe that 90% of blockbuster medicines are only effective for 30-50% of patients. The reason? A “one-size-fits-all” approach to pharmaceutical development and commercialization. At this year’s 22nd Annual Drug Delivery Partnership meeting, a new approach to the pharma value chain is in discussion. […]
Boston-based health and tech start-up calls on patients and clinicians to share their stories to help make new discoveries needed to diagnose and treat rare genetic diseases. Beginning in March, the 2017 Year of Discovery initiative was created to unite clinicians, labs and patients worldwide to make rare disease discoveries, with a special focus on […]
Genetic sequencing is becoming a more popular diagnostic tool; however, even with all the advancements, it only reaches a diagnosis for 1 of 4 patients. Listen to GeneDx’s Kyle Retterer and FDNA’s Dekel Gelbman discuss how next-generation phenotyping (NGP) technology/precision phenomics is making way for a new era in precision medicine, driving up genetic testing […]
The Division of Genetics and Genomics Department of Medicine at Boston Children’s Hospital will present its exciting new Fall Precision Medicine Summit. The event will last for five days from September 18, through September 22. FDNA, an event sponsor and invited speaker, is scheduled to present its leading application, Face2Gene, at the gathering. Face2Gene’s artificial […]
The performance of FDNA’s facial analysis technology, Face2Gene, was recently put up to the challenge of recognizing facial features of children ages 2-6 with CHARGE syndrome compared to a control group of children with other syndromes. The results demonstrate that this technology successfully recognizes children with CHARGE syndrome with a high degree of accuracy (measured […]
In May, FDNA reached out to clinicians and patients globally as part of the Year of Discovery to collect and analyze patient data from a category of syndromes known as Metabolic Disorders and Lysosomal Storage Disorders (LSD) in partnership with Blueprint Genetics and the National MPS Society. As part of this research into new facial analysis and […]
In April 2017, FDNA analyzed patient data from syndromes categorized as Overgrowth Syndromes as part of the Year of Discovery, in partnership with Invitae and Child Growth Foundation. A research team at FDNA, dedicated to making new discoveries with this data, has released new results, in addition to the March RASopathy findings, in the ongoing […]
In March, FDNA reached out to clinicians and patients globally as part of the Year of Discovery to collect and analyze patient data from a category of syndromes known as RASopathies, in partnership with Blueprint Genetics and the Noonan Syndrome Foundation. A research team at FDNA, dedicated to making new discoveries with this data, has released […]